TEBRAZID 500 MG
PYRAZINAMIDE : 500 MG · DIN 00283991 · BAUSCH HEALTH, CANADA INC.
Health Canada status: DORMANT
What is TEBRAZID?
TEBRAZID 500 MG contains PYRAZINAMIDE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 00283991, held by BAUSCH HEALTH, CANADA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 20-Nov-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEBRAZID used for?
TEBRAZID is indicated, in combination with other antituberculosis agents in the treatment of clinical tuberculosis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEBRAZID, and other antibacterial drugs, TEBRAZID should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00283991 |
|---|---|
| Brand name | TEBRAZID |
| Generic / active ingredient | PYRAZINAMIDE : 500 MG |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J04AK01 PYRAZINAMIDE |
| AHFS class | 08:16.04 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 20-Nov-2020 |
| Original market date | 1973-12-31 00:00:00 |
How is it stored and handled?
Store in well-closed container at controlled room temperature (15-30°C).
How is it supplied?
Available in bottles of 120.
What can be used instead?
Other Canadian products sharing ATC code J04AK01 PYRAZINAMIDE. 1 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PDP-PYRAZINAMIDE | 500 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00618810 |
| PMS-PYRAZINAMIDE | 500 MG | TABLET | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02520583 |
Who else supplies PYRAZINAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PYRAZINAMIDE appears in 21 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.